Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations To Four Key Western States


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, is expanding the availability of its Dropless formulations to over 3,000 ophthalmologists in four key states: California, Nevada, Oregon, and Hawaii. These states represent over 290 ambulatory surgery centers (ASCs) where cataract and other ocular surgeries are performed, including California which has the most ASCs dedicated to ocular surgery in the country. Imprimis currently provides two proprietary compounded antibiotic and steroid formulations available in single, injectable intraocular doses administered during ocular surgery. The first formulation contains triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi), and a second variation includes the added antibiotic vancomycin (Tri-Moxi-Vanc). These medications are available with a physician's prescription for individual patients and have been administered in over 40,000 ophthalmic procedures, primarily cataract surgeries.Injectable intraocular drugs can simplify the post-operative process and provide safeguards against bacterial infection and inflammation. They reduce dependence on expensive, topical post-operative eye drop therapy resulting in a significant decrease in the overall cost of the surgical procedure. With Dropless formulations, patients may no longer need to administer multiple topical drops daily thereby largely eliminating patient non-compliance issues. Dropless Therapy has tremendous potential benefit to patients, particularly the physically and economically disadvantaged, along with caregivers, surgeons, staff, and the healthcare system alike. To order Dropless formulations in California, Nevada, Oregon, or Hawaii, ophthalmologists or their representatives should call (858) 704-4040 or visit www.GoDropless.com to reach Imprimis Pharmaceuticals regional associates for account setup and ordering.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsPress Releases